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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYPrevious studies have suggested that breast cancer stem cells (BCSCs) mediate metastasis, are resistant to radiation and chemotherapy,
and contribute to relapse. Although several BCSC markers have been described, it is unclear whether these markers identify the same
or independent BCSCs. Here, we show that BCSCs exist in distinct mesenchymal-like (epithelial-mesenchymal transition [EMT]) and
epithelial-like (mesenchymal-epithelial transition [MET]) states. Mesenchymal-like BCSCs characterized as CD24CD44+ are primarily
quiescent and localized at the tumor invasive front, whereas epithelial-like BCSCs express aldehyde dehydrogenase (ALDH), are prolif-
erative, and are located more centrally. The gene-expression profiles of mesenchymal-like and epithelial-like BCSCs are remarkably
similar across different molecular subtypes of breast cancer, and resemble those of distinct basal and luminal stem cells found in the
normal breast. We propose that the plasticity of BCSCs that allows them to transition between EMT- and MET-like states endows these
cells with the capacity for tissue invasion, dissemination, and growth at metastatic sites.INTRODUCTION
Recent studies have provided strong support for the cancer
stem cell (CSC) hypothesis, which suggests that many can-
cers, including breast cancer, are driven by a subpopulation
of cells that display stem cell properties. These cells may
mediatemetastasis and, by virtue of their relative resistance
to chemotherapy and radiation, contribute to treatment
relapse. Although some studies have indicated a close asso-
ciation between CSCs and the acquisition of an epithelial-
mesenchymal transition (EMT) state (Mani et al., 2008),
other studies have suggested that EMT and CSC states are
mutually exclusive (Tsuji et al., 2008). The process of
EMT plays an important role in embryogenesis as well as
in a number of biological processes associated with cancer
progression (Thiery et al., 2009). During EMT, epithelial
cells lose cell-cell contacts, undergo cytoskeletal remodel-
ing resulting in loss of polarity, and acquire amesenchymal
morphology (Moreno-Bueno et al., 2008). Importantly,
EMT is reversible, and the epithelial phenotype generated
through mesenchymal-epithelial transition (MET) is char-
acterized by expression of E-cadherin and establishment
of cell polarity. Interestingly, a number of pathways that78 Stem Cell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The Authorare known to regulate CSCs, including Notch, hedgehog,
Wingless (Wnt), transforming growth factor-b (TGFb),
and nuclear factor kappa-light-chain-enhancer of activated
B cells (NFkB), also are capable of inducing EMT (Shin et al.,
2010; Takebe et al., 2011; Yoo et al., 2011). However, other
pathways that regulate CSCs, including those involving
bone morphogenetic proteins (BMPs) and human
epidermal growth factor receptor (HER) signaling, promote
MET (Korkaya et al., 2012; Samavarchi-Tehrani et al.,
2010). Further studies are needed to more fully define the
relationship among EMT, MET, and CSCs.
The development of biomarkers to identify BCSCs by our
group and others, as well as validation of in vitro and
mouse models, has facilitated the isolation and character-
ization of BCSC from both murine and human tumors
(Al-Hajj et al., 2003; Dontu et al., 2003; Ginestier et al.,
2007). In human breast cancer, tumor-initiating cells
were first identified by virtue of their expression of the
cell surface marker profile CD24CD44+. In primary breast
xenografts, cells expressing these markers were enriched
for their ability to initiate tumors in immunodeficient non-
obese diabetic (NOD)/severe combined immunodeficiency
(SCID) mice (Al-Hajj et al., 2003). More recently, we haves
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that express the enzyme aldehyde dehydrogenase
(ALDH), as assessed by the ALDEFLUOR assay, are also en-
riched for tumor-initiating characteristics (Ginestier et al.,
2007). Furthermore, in primary breast xenografts,
CD24CD44+ and ALDH identified overlapping, but
nonidentical cell populations, each capable of initiating
tumors in NOD/SCID mice (Ginestier et al., 2007). Tumor
cells that simultaneously expressed both CSC markers
(i.e., CD24CD44+ and ALDH+) displayed the greatest
tumor-initiating capacity, generating tumors in NOD/
SCID mice from as few as 20 cells (Ginestier et al., 2007).
Subsequently, CD44, CD24, and ALDH were reported to
be expressed in CSCs from a wide variety of carcinomas,
including those of the pancreas, colon, lung, ovary, and
prostate gland (Eramo et al., 2008; Huang et al., 2009; Kryc-
zek et al., 2012; Li et al., 2007; Prince et al., 2007). In addi-
tion to carcinomas, these markers have also proven useful
for isolating CSCs from hematologic malignancies (Storms
et al., 1999) and sarcomas. This suggests that CSCs across a
wide variety of malignancies may share marker expression
aswell as biological characteristics. However, it remains un-
clear whether tumors contain multiple types of CSCs and
whether CSC markers identify distinct CSC populations.
Here, we show that BCSCs exist in distinct EMTandMET
states characterized by expression of distinct CSC markers.
We find that the gene-expression profiles of mesenchymal-
like BCSC resemble those of basal stem cells, whereas the
profiles of epithelial-like BCSCs resemble those of luminal
stem cells in the normal breast. Furthermore, we show
that BCSCs are endowed with a plasticity that enables
them to transition between these EMT and MET states.
Based on these studies, we propose that reversible transi-
tions between mesenchymal-like and epithelial-like stem
cell states in a process regulated by the tumor microenvi-
ronment are necessary for these tumor cells to invade and
form metastasis at distant sites.RESULTS
CD24CD44+ and ALDH Identify Anatomically
Distinct BCSCs with Distinct Gene-Expression Profiles
Independent of Molecular Subtype
Previous studies by our group identified CD24CD44+ and
ALDH as BCSCmarkers, with cells displaying either marker
being capable of initiating tumors in NOD/SCID mice (Al-
Hajj et al., 2003; Ginestier et al., 2007). To determine
whether these BCSC markers identify the same or distinct
cell populations, and to localize these populations within
human breast cancers, we performed immunofluorescence
utilizing antibodies against CD44, CD24, and ALDH1, the
ALDH isoformmost commonly expressed in human breastStemcancers (Ginestier et al., 2007). As assessed by immunoflu-
orescence, CD24CD44+ and ALDH1 identified largely
nonoverlapping cell populations in primary human breast
cancers (Figure 1A). Furthermore, these cell populations
were located in anatomically distinct areas. CD24CD44+
cells were located primarily at the tumor-invasive edge
adjacent to the tumor stroma (Figure 1A). In contrast,
ALDH1+ cells were located more centrally, consistent with
our previous studies demonstrating that ALDH+ CSCs are
generated by hypoxia (Conley et al., 2012), in tumor inter-
nal zones. A small population of cells that simultaneously
expressed CD24CD44+ and ALDH1 were identified
(Figure 1A).
To characterize the BCSC populations identified by these
markers, we isolated CD24CD44+- or ALDH-expressing
cell populations from a total of 45 primary human breast
cancers and performed gene-expression analyses using
Affymetrix microarrays. Of 3,677 RNA transcripts that
were elevated in the CD24CD44+ population, 1,724
were diminished in the ALDH+ population (Figure 1B).
Conversely, of the 5,218 mRNA transcripts that were
elevated in the ALDH+ population, 1,362 were diminished
in the CD24CD44+ population (Figure 1C). This suggests
that a large number of genes display reciprocal expression
patterns within CD24CD44+ and ALDH+ populations.
Our group and others have shown that normal and malig-
nant stem cells have the capacity to form spherical colonies
in vitro under anchorage-independent conditions (Dontu
et al., 2003). Therefore, we compared the gene-expression
patterns of CD24CD44+ and ALDH+ fractionated and
tumorsphere cultured cells. Even though many genes
demonstrated reciprocal expression patterns in the
CD24CD44+ and ALDH+ populations, a set of genes ex-
pressed in CD24CD44+ and ALDH+ populations displayed
overlap with those from tumorsphere populations gener-
ated from unsorted cells (Figure S1 available online). This
suggests that despite significant differences between cells
characterized by CD24CD44+ or ALDH expression, both
of these populations share characteristics with tumor-
sphere-forming cells, a property of stemness. These results,
together with prior studies demonstrating the tumor-initi-
ating capacity of both CD24CD44+ and ALDH+ popula-
tions, suggest that these CSC markers identify two stem
cell populations in human breast cancers.
Breast cancers can be subdivided by gene-expression pat-
terns into categories with distinct biological and clinical
characteristics. These include luminal breast cancers,
which express the steroid hormone receptors estrogen re-
ceptor (ER) and progesterone receptor (PR); HER2+ breast
cancers characterized by amplification of the HER2 gene;
and basal breast cancers that are triple negative (TN) in
that they fail to express hormone receptors or display
HER2 amplification. Of interest, although whole-tumorCell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The Authors 79
Figure 1. CD24CD44+ and ALDH+ Identify Anatomically Distinct BCSCs with Distinct EMT and MET Gene-Expression Profiles in
Primary Breast Cancers
(A) Localization of CD24 (magenta), CD44 (green), ALDH1 (red), and DAPI (blue) in clinical samples of human invasive breast carcinoma as
assessed by immunofluorescence staining. Bar: 100 mm.
(B) Venn diagram of the intersection between genes elevated in CD24CD44+ compared with other flow-sorted cells (others) and genes
diminished in ALDH+ compared with ALDH cells (jfold changej > 1.5 for each comparison).
(C) Venn diagram of the intersection between genes diminished in CD24CD44+ versus others and genes elevated in ALDH+ versus ALDH.
(D) Heatmap of genes with opposite expression patterns between CD24CD44+ and ALDH+ (from B and C). Each row represents an RNA
transcript; each column represents a sample (red, high expression). The molecular subtype based on expression of ER, PR, and HER2 is
displayed below the heatmap for each patient sample.
See also Figure S1.
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types, the CD24CD44+ and ALDH+ BCSC populations iso-
lated from these tumors showed a high concordance in
gene expression that was independent of the molecular
subtypes of breast cancer (Figure 1D). Together, these
studies suggest that human breast cancers contain BCSCs
with distinct gene-expression profiles characterized by
either CD24CD44+ or ALDH+. Furthermore, although
tumor-profiling studies of bulk tumor populations revealed80 Stem Cell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The Authordistinct molecular subtypes, the gene-expression patterns
of the ALDH+ andCD24CD44+ BCSCs displayed a remark-
able similarity across molecular subtypes of breast cancer
(Figure 1D).
CD24CD44+ Identifies Mesenchymal-like CSCs,
and ALDH+ Identifies Epithelial-Like BCSCs
Several recent studies have suggested a strong correlation
between CSCs and the EMT, while other studies haves
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(Tsuji et al., 2008). To shed light on this controversy, we
compared expression of EMT- and MET-associated genes
in sorted CD24CD44+ and ALDH+ tumor cells isolated
from primary human breast cancers. As shown in Figure 2,
EMT-associated genes, including vimentin, zinc finger
E-box-binding homeobox 1 (ZEB1), ZEB2, b-catenin
(CTNNB1), and matrix metalloproteinase-1 (MMP9), were
significantly enriched in the CD24CD44+ populations,
whereas expression of these EMT genes was correspond-
ingly decreased in the ALDH+ population. Conversely,
genes associated with the alternative epithelial-like state,
such as cadherin, occludin, claudins, and desmoplakin,
were elevated in the ALDH+ population and correspond-
ingly diminished in the CD24CD44+ cell population.
These results were confirmed by quantitative RT-PCR
(qRT-PCR; Figure 2D). The proliferation marker Ki67 was
preferentially expressed in ALDH+ compared with CD24
CD44+ cells, which is consistent with our previous finding
demonstrating an association between ALDH1 and Ki67
expression in primary human breast cancers (Ginestier
et al., 2007). These studies suggest that in primary human
breast cancers, the CD24CD44+ markers identify mesen-
chymal-like CSCs, whereas ALDH expression identifies
epithelial-like proliferative CSCs.
BCSCs Display Plasticity that Enables Them
to Transition between Epithelial-like and
Mesenchymal-like States
We utilized established breast cancer cell lines as well as
primary tumor xenografts to characterize the biological
characteristics of mesenchymal EMT-like and epithelial
MET-like CSC populations. Our group and others have
previously demonstrated that these cell lines contain
subpopulations expressing CD24CD44+ or ALDH, both
of which are enriched for tumor-initiating potential (Al-
Hajj et al., 2003; Ginestier et al., 2007). We performed
flow cytometry to examine overlap of expression of these
markers. As was the case with primary breast tumors,
breast cancer cell line SUM149 contained CD24CD44+-
and ALDH-expressing cell populations with minimal
overlap (Figure 3A). Similar populations displaying
CD24CD44+ and ALDH+ were found in luminal MCF7
and basal HCC1954 cell lines, as well as in the primary
tumor xenograph UM2, which is of the basal molecular
subtype. Furthermore, as was the case with primary breast
cancers, gene-expression profiling of breast cancer cell
lines of various molecular subtypes (SUM149, HCC1954,
and MCF7) and primary xenografts (MC1 and UM2),
gene-expression profiling revealed that CD24CD44+
cells were enriched for expression of mesenchymal genes,
and ALDH-expressing cells demonstrated a reciprocal
epithelial gene-expression pattern (Figures 2A–2C andStemS2). These results were confirmed by qRT-PCR (Figures
2D and S3).
To determine the degree of cellular plasticity between
EMT- and MET-like CSC states, we isolated CD24CD44+-
and ALDH-expressing cell populations from the basal
breast carcinoma cell line SUM149 and determined the
stability of these phenotypes in culture. Purified
CD24CD44+- or ALDH-expressing cells generated hetero-
geneous populations recapitulating the proportion of
CD24CD44+ and ALDH+ BCSCs present in the original
cell line (Figure 3B). Cellular plasticity in vitro was also
demonstrated with the luminal cell line MCF7. This sug-
gests that BCSCs in multiple molecular breast cancer sub-
types can reversibly transit between epithelial-like and
mesenchymal-like states.
Previous studies have suggested a relationship between
the EMTstate and the ability of cells to mediate tissue inva-
sion andmetastasis. In order to compare the invasive prop-
erties of mesenchymal-like and epithelial-like BCSCs, we
utilized a Matrigel invasion assay. As shown in Figure 3D,
tumor cells that displayed either BCSC marker were more
invasive than bulk tumor populations. Within CSC
marker-positive cell populations, CD24CD44+ cells were
significantly more invasive than ALDH-expressing cells,
and cells that displayed all three stem cell markers demon-
strated the greatest invasive capacity.
Together, these studies suggest a model in which BCSCs
may exist in alternative mesenchymal-like and epithelial-
like states, as depicted in Figure 3E. CD24CD44+ BCSCs
display a mesenchymal phenotype with high invasive
capacity and low proliferative potential. Conversely,
ALDH-expressing BCSCs are characterized by an epithe-
lial-like proliferative state. BCSCs display a plasticity that
allows them to transition between these states.
Mesenchymal and Epithelial BCSCs Resemble Basal
and Luminal Stem Cells in the Normal Mammary
Gland
The relationship between BCSC populations and their
counterparts in the normal mammary gland remains
controversial. The markers alpha 6 integrin (CD49f) and
epithelial cell adhesion molecule (EPCAM) have been uti-
lized to identify a hierarchy of normalmammary cell differ-
entiation. When used in combination, these markers iden-
tify four populations in the human mammary gland:
EPCAM+CD49f epithelial cells, EPCAM+CD49f+ luminal
progenitor cells, EPCAMCD49f+ stem cells, and EPCAM
CD49f stromal cells (Visvader, 2009). We utilized the
nontransformed MCF10A human mammary cell line to
determine the relationship between these markers and
the CD24CD44+ and ALDH+ markers used to characterize
CSCs. Consistent with previous reports, when placed in
tissue culture, EPCAM+CD49f+ cells displayed an epithelialCell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The Authors 81
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E-cadherin (Figure 4B), whereas EPCAMCD49f+ cells dis-
played a mesenchymal morphology (Figure 4A) character-
ized by expression of the EMTmarker vimentin (Figure 4C).
However, these phenotypes were not stable in culture, and
EPCAM+CD49f cells generated double-positive cells and
vice versa (Figure 4A). To determine the relationship be-
tween cell populations identified by expression of these
markers and the BCSC markers CD24CD44+ and ALDH,
we performed serial flow cytometry using both sets of
markers. EPCAMCD49f+ mesenchymal-like cells were en-
riched for expression of CD24CD44+ (Figure 4D), whereas
EPCAM+CD49f+ epithelial-like cells were enriched for
ALDHexpression as assessed by theALDEFLUOR assay (Fig-
ure 4D). Furthermore, these populations were distinct,
with little overlap (Figure 4E). As was the case for breast
cancer cells, gene-expression analysis of sorted CD24
CD44+ and ALDH+ populations isolated from the non-
transformed cell line MCF10A demonstrated that these
cells express genes characteristic of mesenchymal (basal)
and epithelial phenotypes, respectively (Figure 4F). We
verified expression of a subset of these genes by qRT-PCR
(Figure S4).
ALDH+-Expressing Normal Breast Cells Display High
Proliferative Potential and Multilineage
Differentiation Capacity
We utilized primary human breast tissue obtained from
reduction mammoplasties to determine the gene-expres-
sion profiles of cell populations expressing these markers.
As was the case forMCF10A cells, EPCAMCD49f+ cells iso-
lated from normal breast expressed mesenchymal markers,
whereas EPCAM+CD49f+ cells primarily expressed epithe-
lial markers (Figure 5).
To assess the self-renewal capacity and differentiation
potential of different cell populations, flow-cytometry-
sorted populations of primary human mammary cells ob-
tained from breast reduction surgery were transplanted
into the cleared fat pads of NOD/SCID mice that had
been humanized by addition of human mammary fibro-Figure 2. Specific EMT Markers Have Opposite Expression Pattern
Tumors
(A) Expression of EMT/MET markers in CD24CD44+ versus others
p = 0.138), Ki67 (probe 224713_at p = 0.229), all other EMT markers lis
for ZEB1 (probe 212764_at p = 0.106), ZEB2 (probe 228333_at p = 0.3
p = 0.203, probe 231022_at p = 0.203), CLDN8 (probe 214598_at p =
listed are significant with p < 0.05 for ALDH+ versus ALDH.
(B) For CD24CD44+ versus others flow-sorted profile data sets, heatm
(C) As in (A), but for ALDH+ versus ALDH profile data sets.
(D) Gene-expression levels measured by qRT-PCR confirm the results o
mean ± SD. The fold changes are significant with p < 0.05 for CD24
See also Figure S2 and S3.
Stemblasts (Liu et al., 2006). Within the CD49f+ population,
both EPCAM+ and EPCAM cells were able to generate
mammary structures containing both epithelial andmyoe-
pithelial cell lineages (Figure 6A). To further characterize
these populations, we determined the relationship be-
tween expression of CD49f and EPCAM with that of the
CSC markers CD24CD44+ and ALDH+. As was the case
with MCF10A cells, EPCAMCD49f+ cells were enriched
for CD24CD44+, whereas EPCAM+CD49f+ cells were en-
riched for ALDH expression (Figure 6B) with little overlap
between these populations. Gene-expression analysis of
sorted CD24CD44+ and ALDH+ cells demonstrated that
these cell populations expressed genes characteristic of
mesenchymal and epithelial phenotypes, respectively (Fig-
ure 5B), and this was verified by qRT-PCR (Figure 5C).
Despite the observation that ALDH+ cells were predomi-
nantly contained within the EPCAM+CD49f+ population,
this ALDH+ population constituted only 6% of total
EPCAM+CD49f+ cells. Furthermore, within the EPCAM+
CD49f+ population, only ALDH+ cells were able to generate
bilineage colonies in vitro (Figures 6C and S5A) and
generate ductal/alveolar structures in 3D Matrigel cultures
(Figures 6D and S5B), consistent with a recent report (She-
hata et al., 2012). These experiments expand on previous
work by suggesting that in the normal mammary gland,
the EPCAM+CD49f+ cell population is heterogeneous and
consists of an ALDH+ subcomponent with high prolifera-
tive capacity and multilineage differentiating potential,
and an ALDH component at is luminal restricted with
lower proliferative potential.
We utilized immunofluorescence to localize cell popula-
tions identified by the stem cell markers in normal human
breast tissue. CD24CD44+ cells were located in a basal
location within ductal structures frequently associated
with ductal branch points (Figure 6E). In contrast,
ALDH1+ cells were located in an abluminal location within
lobules (Figure 6E). The quantitation of each cell popula-
tion is shown in Figure S5C. These results suggest that
the human mammary gland contains two stem cell
populations, each of which is capable of self-renewal ands in CD24CD44+ and ALDH+ Cells from Clinical Patient Breast
and ALDH+ versus ALDH. Except for MMP9 (probe 203926_s_at
ted are significant at p < 0.05 for CD24CD44+ versus others. Except
36), CDH1 (probe 201131_s_at p = 0.209), OCLN (probe 209925_at
0.15), and DSP (probe 200606_at p = 0.46), all other EMT markers
ap of EMT markers (jfold changej > 1.5).
btained with Affymetrix array HU133 Plus 2.0. Error bars represent
CD44+ versus others.





Figure 3. BCSC Display a Cellular Plasticity that Allows Them to Transit between EMT and MET States
Basal breast cancer cell lines SUM149 and MCF7 were immunostained with CD24 and CD44 antibodies, and subsequently with ALDEFLUOR.
The four cell subpopulations defined by the ALDEFLUOR and CD24CD44+ phenotypes were separated by fluorescence-activated cell sorting
(FACS).
(A) The percentages shown in the diagram show the representation of the cell subpopulations in the total tumor cell population and the
overlap between the ALDEFLUOR phenotype and the CD24CD44+ phenotype.
(B) The unsorted SUM149 cells and the sorted CD24CD44+ and ALDH+ populations as described in (A) were placed in culture for 10 days,
and the resulting cells were reanalyzed by FACS for ALDEFLUOR, CD24, and CD44. *p < 0.05 (percentage of ALDH+ cells generated from the
ALDH+ population compared with that generated from parental cells). &p < 0.05 (percentage of CD24CD44+ cells generated from the
CD24CD44+ population compared with that generated from parental cells).
(C) The unsorted MCF7 cells and the sorted CD24CD44+ and ALDH+ populations as described in (A) were placed in culture for 10 days, and
the resulting cells were reanalyzed by FACS for ALDEFLUOR, CD24, and CD44. *p < 0.05 (percentage of ALDH+ cells generated from ALDH+
population compared with that generated from parental cells). &p < 0.05 (percentage of CD24CD44+ cells generated from the CD24CD44+
population compared with that generated from parental cells).
(D) The sorted four populations of SUM149 as described in (A) were assessed for invasive capacity utilizing the Matrigel invasion assay.
Scale bar, 200 mm.
(E) Hypothetical models show the characteristics of two different states of BCSCs. *p < 0.05; error bars represent mean ± SD.
See also Figure S6.
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display the BCSC marker CD24CD44+ express basal/
mesenchymal-like genes and are located in the basal layer
of mammary ducts. In contrast, EPCAM+CD49f+ALDH+
cells are highly proliferative, display an epithelial-like
gene-expression profile, and are present in an abluminal
location in mammary lobules.84 Stem Cell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The AuthorDISCUSSION
Utilizing primary breast cancer tissue as well as primary
xenografts and established cell lines, we demonstrate that
BCSCs exist in distinct mesenchymal-like and epithelial-
like states that can be identified by specific marker
expression and display distinct gene-expression profiles.s
Figure 4. Identification of Mesenchymal-like and Epithelial-like States in Nontransformed MCF10A Cells
(A) Cells were immunostained with EPCAM and CD49f antibodies. EPCAM+CD49f+ and EPCAMCD49f+ cells were separated by FACS and plated
in culture for 10 days. FACS analysis for EPCAM and CD49f was then repeated. Scale bar, 200 mm.
(B and C) Total RNA was extracted from the sorted EPCAM+CD49f+ cells and EPCAMCD49f+ cells, and the expression level of E-cadherin,
vimentin, and TATA-binding protein (TBP) was measured by qRT-PCR. *p < 0.05; error bars represent mean ± SD.
(D) Cellswere immunostainedwith EPCAMand CD49f antibodies, and subsequently stainedwith CD24/CD44or ALDEFLUOR. Inset displays the
negative control; cells incubated with DEAB, the specific inhibitor of ALDH, were used to establish the baseline fluorescence of these cells.
(E) Cells were immunostained with CD24 and CD44 antibodies, and subsequently with ALDEFLUOR. The four cell subpopulations defined by
the ALDEFLUOR and CD24CD44+ phenotypes were separated by FACS. The percentages shown in the diagram depict cell subpopulations
and the overlap between the ALDEFLUOR-positive phenotype and the CD24CD44+ phenotype. Inset displays the negative control; cells
incubated with DEAB, the specific inhibitor of ALDH, were used to establish the baseline fluorescence of these cells.
(F) Total RNA was extracted from the four populations as described in (E) and used for Affymetrix array (HU133 Plus 2.0) analysis. The fold
change for EMT/MET markers was compared among ALDH+, ALDH, CD24CD44+, and others.
See also Figure S4.
Stem Cell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The Authors 85
Stem Cell Reports
Characterization of Breast Cancer Stem Cell States
AB
C
Figure 5. Characterization of CD24CD44+ Cells and ALDH+
Epithelial Cells Isolated from Normal Breast Tissues
(A) Cells were immunostained with CD24 and CD44 antibodies, and
subsequently stained with ALDEFLUOR. The four cell sub-
populations defined by the ALDEFLUOR and CD24CD44+ pheno-
types were separated by FACS. The percentages in the diagram
represent the cell subpopulations as a representative of the total
tumor cell population and the overlap between the ALDEFLUOR
phenotype and the CD24CD44+ phenotype. Inset displays the
negative control; cells incubated with DEAB, the specific inhibitor
of ALDH, were used to establish the baseline fluorescence of these
cells.
86 Stem Cell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The Author
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primarily quiescent and are located at the tumor-invasive
front, whereas epithelial-like CSCs expressing ALDH are
proliferative and located more centrally within tumors.
Despite the fact that different molecular subtypes of
breast cancer can be distinguished based on their gene-
expression profiles, the EMT- and MET-like BCSC gene-
expression profiles are remarkably similar across these
different molecular subtypes. In addition to suggesting a
potential common cell of origin for different breast
cancer subtypes, these results also have important clinical
implications. Currently, breast tumors are subdivided
into subtypes based on molecular profiling, which reflects
the expression of steroid hormone receptors (ER and
PR) as well as HER2 gene amplification. This classification
dictates the therapeutic modality utilized, such as hor-
mone therapy, HER2 blockade, or chemotherapy. The
demonstration of common gene-expression profiles in
BCSCs across molecular subtypes suggests that agents
targeting BCSCs may have utility across molecular sub-
types of breast cancer. Such CSC-targeting therapies could
be added to the current subtype-specific therapies that
target bulk tumor populations. Our recent report that
HER2 drives luminal BCSCs in the absence of HER2 gene
amplification supports this approach (Ithimakin et al.,
2013).
Recent studies have suggested a commonality between
CSCs and the EMT state, whereas other studies have sug-
gested that these states are mutually exclusive (Tsuji
et al., 2008). Our work provides an explanation for these
contradictory findings by demonstrating that BCSCs can
exist in alternative epithelial-like and mesenchymal-like
states. The mesenchymal-like state is associated with
expression of mesenchymal markers, relative quiescence,
and high invasive capacity, whereas the epithelial-like state
is associated with expression of epithelial markers, estab-
lishment of cell polarity, and extensive proliferation.
Furthermore, we demonstrate that BCSCs display a cellular
plasticity that enables them to transition between epithe-
lial-like and mesenchymal-like states. The transition
between these states may be regulated by the tumor(B) Expression of EMT/MET markers in CD24CD44+ versus others
and ALDH+ versus ALDH of normal breast as assessed by Affymetrix
array HU133 Plus 2.0.
(C) To confirm the gene-expression results for EMT/MET markers, we
measured the mRNA expression level for Vimentin, ZEB1, Claudin 3,
and Ki67 in a set of breast tumor cells sorted for ALDH+/ALDH,
CD24CD44+/others by qRT-PCR. Gene-expression levels measured
by qRT-PCR confirm the results obtained with the Affymetrix array
HU133 Plus 2.0. The fold changes are significant with p < 0.05 for
CD24CD44+ versus others or ALDH+ versus ALDH. Error bars






Figure 6. Normal Human Breast Contains Distinct
Basal and Luminal Stem Cells that Express EMT
and MET Markers, Respectively
(A) Cells isolated from reduction mammoplasty tis-
sue were immunostained with lineage markers
(Lin), EPCAM, and CD49f antibodies, and were first
gated based on viability (DAPI) and lineage
markers. The sorted cells (LinEPCAM+CD49f+ and
LinEPCAMCD49f+ cells) were injected into the No.
4 mammary gland fat pads, which were previously
humanized with normal human breast fibroblasts.
After about 2 months, the mice were sacrificed and
the outgrowths that were generated in the fat pads
were assessed by hematoxylin and eosin staining.
Scale bar, 100 mm.
(B) Cells were immunostained with EPCAM and CD49f
antibodies followed by CD24/CD44 or ALDEFLUOR.
Inset displays the negative control: cells incubated
with DEAB, the specific inhibitor of ALDH, were used
to establish the baseline fluorescence of these cells.
(C) Cells were immunostained with Lin, EPCAM, and
CD49f antibodies, and subsequently withALDEFLUOR.
The cells were first gated based on viability (DAPI)
and lineage markers. The sorted cells (LinEPCAM+
CD49f+ALDH+ cells and LinEPCAM+CD49f+ALDH
cells) were grown in differentiating conditions on
collagen-coated plates for 12 days and the number of
colonies generated was assessed.
(D) Sorted cells (LinEPCAM+CD49f+ALDH+ and
LinEPCAM+CD49f+ALDH cells) were cultured in 3D
Matrigel culture for 3 weeks and the number of
branched structures generated was assessed.
(E) Localization of CD24 (magenta), CD44 (green),
ALDH1 (red), and DAPI (blue) in normal breast tissue
as assessed by immunofluorescence staining. Yellow
arrow, CD24CD44+ cells; white arrow, ALDH1+ cells.
Scale bar, 100 mm.
See also Figure S5.
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Characterization of Breast Cancer Stem Cell Statesmicroenvironment. For example, TGFb and IL-6 generated
in the tumor microenvironment induce EMT, whereas in-
hibition of TGFb signaling and stimulation of BMPs induce
MET. BCSC signal transduction pathways involving Wnt
and NFkB induce EMT, whereas HER2 induces MET (Liu
et al., 2012a). In addition, microRNA circuits within BCSCs
may further regulate EMT/MET transitions by coordinately
regulating multiple pathways (Liu et al., 2012b). We
demonstrate that mesenchymal-like BCSCs tend to be
located at the tumor-invasive front, whereas ALDH+
epithelial-like BCSCs are located in interior hypoxic zones
(Conley et al., 2012). Together, these findings suggest a
model in which mesenchymal-like BCSCs mediate tumor
invasion into the blood, where they survive due to anoikis
resistance and formmicrometastasis in distant organs. The
tumor microenvironment at these sites induces a MET that
is required for BCSC self-renewal. This generates additional
BCSCs, as well as differentiated cells that recapitulate the
cellular hierarchy at metastatic sites. The plasticity of
CSCs that allows them to transition between mesen-
chymal-like and epithelial-like states may play a critical
role in the ability of these cells to formmetastasis at distant
sites, as illustrated in Figure S6. Several recent studies that
demonstrated the importance of cellular plasticity in
metastasis support such a model (Biddle et al., 2011;
Thompson and Haviv, 2011). This model is also supported
by studies demonstrating that in patients with metastatic
breast cancer, circulating tumor cells and bone marrow
micrometastasis are highly enriched for cells expressing
the EMT BCSC marker CD24CD44+ (Sheridan et al.,
2006). Furthermore, these cells do not express the prolifer-
ation marker Ki67, consistent with their quiescence.
Conversely, macrometastases express the stem cell markers
ALDH and CD24CD44+ in proportions similar to those
found in primary tumors.
The relationship between BCSCs and stem cells in the
normal mammary gland has not been defined. Recent
studies in mouse mammary glands suggested the existence
of separate basal and luminal stem cells. Under normal
developmental conditions, each stem cell population gives
rise to cells restricted to either the basal or luminal lineage
(Van Keymeulen et al., 2011). However, transplantation of
these cells into clearedmammary fat pads of recipient mice
uncovers their plasticity, since either one of these cell pop-
ulations is capable of regenerating an entire mammary tree
(Keller et al., 2012). The existence of separate luminal and
basal stem cells has also been reported in the prostate,
where both populations have the capacity to give rise to
prostate carcinomas (Tokar et al., 2005). Our study suggests
that the human mammary gland may display a similar
organization, containing basal stem cells located within
mammary ducts that are CD24CD44+EPCAMCD49f+,
as well as luminal stem cells located in terminal lobules88 Stem Cell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The Authorwhich are EPCAM+CD49f+ALDH+. It was previously sug-
gested that basal and BRCA1-associated breast carcinomas
originate from EPCAM+CD49f+ luminal progenitor cells
(Proia et al., 2011; Molyneux et al., 2010). However, our
studies indicate that the populations defined by expression
of EPCAM and CD49f are heterogeneous. The majority of
EPCAM+CD49f+ cells isolated from the normal mammary
gland are indeed luminal progenitors. However, approxi-
mately 6% of this population, as defined by expression of
ALDH, is characterized by extensive self-renewal capacity
as well as the capacity to generate multilineage structures
when transplanted into the humanized cleared fat pad of
NOD/SCID mice. These results, as well as the gene-expres-
sion profile of this cell population, suggest that rather than
being luminal progenitors, these cells are more accurately
characterized as epithelial-like stem cells. Their location
in terminal lobules is consistent with previous reports sug-
gesting that ‘‘cap’’ cells in terminal lobules have stem cell
properties (Shackleton et al., 2006; Smalley and Ashworth,
2003; Woodward et al., 2005). The self-renewing prolifera-
tive state of ALDH+ luminal stem cells may increase their
susceptibility to carcinogenic mutations, making them a
logical cell of origin for human breast cancer. Our previous
study demonstrating expansion of lobules containing
ALDH1-expressing cells associatedwith loss ofheterozygos-
ity in breast cancer 1 (BRCA1, early onset)mutation carriers
is consistent with such a model (Liu et al., 2008). Further-
more, our studies showed that both basal and luminal
breast cancer subtypes have these two different BCSC pop-
ulations—one characterized as CD24CD44+ and the other
characterized by ALDH expression. Although these BCSC
populations are found across molecular subtypes of breast
cancer, their proportion may vary across these subtypes.
Our group and others have shown that luminal breast can-
cers are enriched in ALDH-expressing CSCs relative to
CD24CD44+ cells. The preponderance of ALDH-express-
ing CSCs is most pronounced in HER2+ breast cancers.
This is consistent with previous findings that HER2 is an
important regulator of CSC self-renewal in both HER2+
(Korkaya et al., 2008) and luminal (Ithimakin et al., 2013)
breast cancer. In contrast, basal breast cancers are enriched
in CD24CD44+ CSCs, and in claudin-low breast cancers
the majority of cells are CD24CD44+ (Prat et al., 2010).
Interestingly, these tumors display a mesenchymal
morphology and exhibit aggressive clinical behavior. The
observation that different molecular subtypes of breast
cancer are characterized by distinct mutations (Cancer
Genome Atlas Network, 2012) suggests that both genetic
and microenvironmental factors may contribute to breast
BCSC phenotypes. The enrichment of ALDH-expressing
CSCs in HER2+ breast cancer and CD24CD44+ CSCs in
basal/claudin-low breast cancers may contribute to the
aggressive clinical behavior of these subtypes.s
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Characterization of Breast Cancer Stem Cell StatesIn summary, our studies suggest that BCSCs can exist in
alternativemesenchymal-like and epithelial-like states that
are reflective of their normal counterparts. The plasticity of
BCSCs that allows them to undergo reversible EMT/MET
transitions regulated by the tumor microenvironment
may be necessary for successful metastatic colonization. A
number of CSC-targeting agents are now entering clinical
trials. Our studies suggest that it may be necessary to
target alternative CSC states to eliminate this clinically
important tumor cell population.EXPERIMENTAL PROCEDURES
Patients and Clinical Samples
We made the following comparisons on flow-sorted samples from
breast cancer patients or breast cancer cell lines: (1) CD24CD44+
versus all other flow-sorted cells obtained from GSE7513 in the
Gene Expression Omnibus (GEO) (patients 32–56 years old), (2)
ALDH+ versus ALDH obtained from 16 breast cancer patients
(35–60 years old), and (3) CD24CD44+ versus all other flow-sorted
cells and ALDH+ versus ALDH from breast cell lines MCF10A,
SUM149, and primary xenograft MC1, and normal breast epithe-
lial cells from patients (18–40 years old).
Data Analysis
Weanalyzedgene-expressionarraysusing thePartekGenomicsSuite.
For each profile data set, we pretreated the data by Quantile normal-
ization andmade a log2-base conversion. Principal-component anal-
ysiswas conducted to determine and removeoutliers. Thepvalues of
genes were calculated by two-sample t test. Expression values were
visualized as heatmaps by the intensity plot function in Partek.
Immunostaining
For ALDH1, CD24, CD44, and DAPI quadruple fluorescent stain-
ing, paraffin-embedded sections of breast tumors or normal breast
tissues were deparaffinized in xylene and rehydrated in graded
alcohol. Antigen enhancement was done by incubating the sec-
tions in citrate buffer pH 6.0 (Dakocytomation) as recommended
by the manufacturer. CD24 antibody (Neomarkers), ALDH1 anti-
body (BD Biosciences), and CD44 antibody (Thermo Scientific)
were used at a 1:50 dilution and incubated for 1 hr. Alexa Fluor
647-, Alexa Fluor 546-, and Alexa Fluor488-labeled secondary anti-
bodies (Invitrogen) were used at a 1:200 dilution and incubated for
20 min. Nuclei were counterstained with DAPI/antifade (Invitro-
gen; blue color in the staining) and coverslipped. Sections were
examined with a fluorescence microscope (EVOS FL; AMG).
Cell Culture
The breast cancer cell lines SUM149 (Asterland) (Neve et al., 2006)
and MCF10A (ATCC) were cultured as previously described (Liu
et al., 2012b).
Flow Cytometry
Core biopsies and normal breast tissues were obtained and
placed immediately in cold RPMI-1640 supplemented with 10%Stemheat-inactivated newborn calf serum (HINCS; Invitrogen). In sum-
mary, the samples were digested in collagenase and 1 3 106 single
cells were resuspended, incubated for 15 min with anti-CD44,
anti-CD24, and anti-lineage mixture antibodies (polyethylenegly-
col-conjugated anti-CD2, anti-CD3, anti-CD10, anti-CD16, anti-
CD18, anti-CD31, and anti-CD140B; PharMingen) using the
manufacturer’s suggested concentrations. They were then flowed
by the ALDEFLUOR assay (Stem Cell Technologies) as described
previously (Ginestier et al., 2007) and analyzed by MoFlo Astrios
flow cytometry. The negative control for antibodies included cells
incubatedwith isotype control antibodies for each color. The nega-
tive control for the ALDEFLUOR assay was cells incubatedwith the
specific inhibitor of ALDH, diethylaminobenzaldehyde (DEAB),
whichwas used to establish the baseline fluorescence of these cells.
Side and forward scatter were used to eliminate debris and cell
doublets, and the Lin cells were further analyzed for expression
of the CD44/CD24 and ALDH markers. The detailed procedure
for cell lines and cells from primary xenografts was described
previously (Liu et al., 2012b).
Invasion Assay
Assayswere done in triplicate in invasion chambers precoatedwith
reduced growth factor matrix from BD Biosciences. Cells were
added to the upper chamber in 200 ml of serum-free medium.
For the invasion assay, 20,000 cancer cells were seeded on the
coated chamber, and the lower chamber was filled with 600 ml
ofmedium (Cambrex) with FBS. After 37 hr of incubation, the cells
on the underside of the upper chambers were stainedwith the blue
stain in the Cell Invasion Assay Kit (ECM550; Chemicon) and
counted by light microscopy.
Normal Breast-Derived Cell Implantation into the
Cleared Fat Pads of NOD/SCID Mice
Three-week-old female NOD/SCID mice were anesthetized by an
i.p. injection (Liu et al., 2006). The No. 4 inguinal mammary
glands were cleared and humanized with 2.5 3 105 nonirradiated
telomerase immortalized normal human mammary fibroblasts (a
generous gift from John Stingl and Connie Eaves, Terry Fox Labo-
ratory) and 2.5 3 105 irradiated (4 Gy) fibroblasts as previously
described (Liu et al., 2006). A 60-day release estrogen pellet
(0.18 mg/pellet; Innovative Research of America) was placed s.c.
on the back of the mouse’s neck via a trocar. The sorted cells
were then mixed with 2.5 3 105 normal human mammary fibro-
blasts, resuspended in 50 ml of 1:1 Matrigel/5% serum Ham’s
F-12, and injected into each of the cleared fat pads. All of the im-
plantation experiments were repeated five times using cells from
different patients, with three mice implanted per patient sample.
3D Matrigel Culture
3D cultures in Matrigel were established as previously described
(Weaver and Bissell, 1999). Briefly, we suspended the sorted cells
in 1 ml of BD Matrigel Matrix (354234; BD Biosciences) and
Ham’s F-12 medium (BioWhittaker) with 5% serum at a ratio of
1:1, and plated 1 ml of the mixture into one well of 24-well cold
plates. Each group of cells was plated in quadruplicate. After the
Matrigel was solidified, 0.5 ml of Ham’s F-12 medium
(BioWhittaker) with 5% serum was added to the top of theCell Reports j Vol. 2 j 78–91 j January 14, 2014 j ª2014 The Authors 89
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least three different patients.
Statistical Analysis
Results are presented as the mean ± SD for at least three repeated
individual experiments for each group. The mean and SD were
determined on the basis of an analysis of at least three replicates
using Microsoft Excel. Statistical differences were determined by
using ANOVA and Student’s t test for independent samples. A value
of p < 0.05 was considered statistically significant.
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